Resource item

Item 9 Labs Corp. will present at Roth’s 34th Annual Conference on March 15

PHOENIX, March 8, 2022 /PRNewswire/ — Item 9 Labs Corp. (OTCQX: INLB) (“the “Company”) – a vertically integrated cannabis dispensary franchisor and operator that manufactures premium, award-winning products – announced today that its management team will participate in the 34and Annual Roth Conference, which takes place March 13-15, 2022 in Dana Point, California. The management team is available to meet with investors throughout the conference, and the company’s CEO Andrew Bowden will present the tuesday march 15.

The annual Roth Conference offers companies an extraordinary platform for building relationships with existing and potential institutional and private investors. This year’s conference will bring together senior executives from approximately 500 private and public companies from a wide variety of industries, including AgTech, Consumer, Energy, Health & Wellness, Healthcare, Industrial Growth, Metals and Mining, Sustainability, Services and Technology . The conference format includes one-on-one and breakout sessions, analyst-selected fireside chats, industry topic panels, on-demand presentations and live entertainment.

Section 9 Labs Corp. Presentation

Bowden will present an overview of the company that includes its award-winning Item 9 Labs cannabis products, its Unity Rd. dispensary franchise brand, and recent momentum and highlights. He also plans to talk about the current challenges of expanding the industry and how the combination of his brands offers a viable solution.

  • Dated: Tuesday, March 15, 2022
  • Time: 2:20 p.m. PT
  • Location: The Ritz-Carlton, Niguel Lagoon in Dana Point, California
  • Registration: Contact a Roth sales representative at (800) 678-9147 or submit an enrollment request here.

1-1 Meetings with the management team

Bowden will be joined by Chief Strategy Officer jeffrey rassasFinancial director Bobby Mikkelsen and Head of Franchise Michael Weinberger for one-on-one sessions with current and potential investors.

  • Appointment: Monday March 14Tuesday, March 15, 2022
  • Times: 8:00 a.m. – 6 p.m. PT
  • Registration: Interested parties are encouraged to contact their Roth salesperson for availability and meeting scheduling.

For more information on Item 9 Labs Corp. and its marks, visit https://item9labscorp.com.

About Item 9 Labs Corp.
Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor that offers premium products from its large-scale cultivation and production facilities in the United States. Award-winning brand Item 9 Labs specializes in the best products and user experience across multiple cannabis categories. The company also offers a unique dispensary franchise model through the nationwide Unity Rd. retail brand. By lowering barriers to entry, franchising provides an opportunity for new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings industry best practices to markets nationwide through a distinctive retail experience, culture capabilities and product innovation. The seasoned management team combines a diverse skill set with deep experience in the cannabis industry, franchising and capital markets to lead a new generation of public cannabis companies that deliver transparency, consistency and well-being. Based in Arizona, the company is currently expanding its operating space by more than 640,000 square feet on its 50-acre site, one of the largest properties in Arizona zoned for growing and growing flowers. For more information, visit item9labscorp.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, the risks and effects of judicial and administrative proceedings and governmental proceedings. regulation, particularly in a foreign country, future financial and operating results, competition, general economic conditions, proposed transactions that are not legally binding on the company and the ability to manage and pursue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this press release include the introduction of new technologies, market conditions and those set forth in any reports or documents we file from time to time. another with the SEC. We undertake no obligation to revise or update these statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unforeseen events.

Media Contact:
Section 9 Labs Corp.
Jayne Levyvice president of communications
Phone: 480-542-9421
E-mail: [email protected]

Investor contacts:
Section 9 Labs Corp.
Phone: 800-403-1140
E-mail: [email protected]

SOURCE Element 9 Labs Corp.